Amphastar Pharmaceuticals, Inc.
General ticker "AMPH" information:
- Sector: Health Care
- Industry: Pharmaceuticals
- Capitalization: $1.4B (TTM average)
Amphastar Pharmaceuticals, Inc. follows the US Stock Market performance with the rate: 9.2%.
Estimated limits based on current volatility of 1.8%: low 27.03$, high 28.04$
Factors to consider:
- Total employees count: 2028 (+15.2%) as of 2024
- US accounted for 96.7% of revenue in the fiscal year ended 2024-12-31
- Top business risk factors: Dependence on key products, Supply chain disruptions, Geopolitical risks, Regulatory and compliance, Intellectual property risks
- Earnings for 9 months up through Q3 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [28.12$, 44.76$]
- 2025-12-31 to 2026-12-31 estimated range: [26.41$, 42.45$]
Financial Metrics affecting the AMPH estimates:
- Negative: with PPE of 9.9 at the end of fiscal year the price was very high
- Positive: Operating profit margin, % of 28.06 > 18.64
- Positive: 6.82 < Operating cash flow per share per price, % of 11.48
- Negative: negative Industry operating cash flow (median)
- Positive: 41.86 < Shareholder equity ratio, % of 46.42 <= 63.39
- Negative: negative Industry operating income (median)
- Positive: Return on assets ratio (scaled to [-100,100]) of 9.21 > 6.04
- Positive: Interest expense per share per price, % of 1.63 <= 3.41
Short-term AMPH quotes
Long-term AMPH plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | $498.99MM | $644.39MM | $731.97MM |
| Operating Expenses | $391.49MM | $447.41MM | $526.55MM |
| Operating Income | $107.50MM | $196.99MM | $205.42MM |
| Non-Operating Income | $8.54MM | $-25.63MM | $-15.65MM |
| Interest Expense | $1.85MM | $27.16MM | $30.34MM |
| R&D Expense | $74.77MM | $73.74MM | $73.91MM |
| Income(Loss) | $116.04MM | $171.36MM | $189.76MM |
| Taxes | $23.48MM | $31.83MM | $29.67MM |
| Other Income(Loss) | $-1.18MM | $-1.98MM | $-0.57MM |
| Profit(Loss)* | $91.39MM | $137.54MM | $159.52MM |
| Stockholders Equity | $528.66MM | $639.42MM | $732.30MM |
| Inventory | $103.58MM | $105.83MM | $153.74MM |
| Assets | $741.99MM | $1,512.91MM | $1,577.47MM |
| Operating Cash Flow | $89.18MM | $183.50MM | $213.39MM |
| Capital expenditure | $24.03MM | $38.17MM | $41.04MM |
| Investing Cash Flow | $-32.78MM | $-649.12MM | $-124.93MM |
| Financing Cash Flow | $-26.44MM | $454.09MM | $-80.95MM |
| Earnings Per Share** | $1.88 | $2.85 | $3.29 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.